OncLive TV

Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

May 31st 2025

Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.

Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanced NSCLC With c-MET Overexpression

May 31st 2025

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin for the treatment of locally advanced or metastatic NSCLC with c-MET overexpression.

Dr Hernandez-Ilizaliturri on the Design of an Observational Study of Immunologic Changes With Venetoclax in CLL

May 31st 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC

May 30th 2025

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Dr Desai on the PATINA Study of a Palbociclib-Based Regimen in HR+/HER2+ Metastatic Breast Cancer

May 30th 2025

Neelam Desai, MD, highlights the phase 3 PATINA study evaluating a palbociclib-based regimen in HR-positive/HER2-positive metastatic breast cancer.

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

May 30th 2025

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Dr Cortese on Future Directions for the Multiomic Investigation of Venetoclax in CLL

May 30th 2025

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Dr Matrana on Advantages and Challenges of the Expanding First-Line RCC Treatment Paradigm

May 30th 2025

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

Dr Burke on CLL Treatment Challenges in Community vs Academic Health Care Settings

May 30th 2025

John M. Burke, MD, discusses the challenges associated with using venetoclax for CLL management across both community and academic oncology settings.

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

May 30th 2025

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia

May 30th 2025

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Dr Vento on the Role of IO/TKI Combos in Non–Clear Cell RCC

May 29th 2025

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

May 29th 2025

Dr Farid on the Clinical Utility of Tabelecleucel in R/R EV+ PTLD

May 29th 2025

Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.

Dr Maroto-Martin on the Mechanism of MZB1-Targeted CAR T-Cell Therapy in Myeloma and Waldenström Macroglobulinemia

May 29th 2025

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Dr Bardia on Efficacy Data from the DESTINY-Breast06 Trial of T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer

May 29th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia

May 29th 2025

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

May 28th 2025

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Dr Merrell on Current Treatment Modalities for Gliomas

May 28th 2025

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.

Dr Atluri on TKI Selection in Chronic Myeloid Leukemia

May 28th 2025

Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.